A review of the effects of tibolone on the skeleton

Bibliography

• ANONYMOUS: Consensus Development Conference. Diagnosis, prophylaxis, and treatment of osteoporosis. iAm. Med. i (1993) 94:646–650.
   Google Scholar
• CUMMINGS SR, MELTON LJ III: Epidemiology and outcomes of osteoporotic fractures. iLancet i (2002) 359:1761–1767.
   PubMed Web of Science ®Google Scholar
• WORLD HEALTH ORGANIZATION: Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. iWorld Health Organ. Tech. Rep. Ser. i (1994) 843:1–129.
   PubMed Web of Science ®Google Scholar
• DEVOGELAER JP: How do you know who needs prevention or treatment? iBaillie' re's Clin. Rheum. i (1997) 11:539–563.
   PubMed Web of Science ®Google Scholar
• MELTON LJ 3rd, CHRIS CHILLES EA, COOPER C, LANE AW, RIGGS BL: Perspective. How many women have osteoporosis? iBone Miner. Res. i (1992) 7:1005–1010.
   Google Scholar
• COOPER C: Epidemiology of osteoporosis. In: iPrimer on the Metabolic Bone Diseases i and Disorders of Mineral Metabolism edn). Section VI Metabolic Bone Diseases. Favus MJ (Ed.), American Society for Bone and Mineral Research, Washington DC, (2003) Chap. 49: 307–313.
   Google Scholar
• NAGANT DE DEUXCHAISNES C, DEVOGELAER JP: Increase in the incidence of hip fractures and of the ratio of trochanteric to cervical hip fractures in Belgium. iCakil Tissue Int. i (1988) 42:201–203.
   PubMed Web of Science ®Google Scholar
• CRANNEY A, GUYATT G, GRIFFITH L iet al.: i IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis. iEndocr. Rev i (2002) 23:570–578.
   Google Scholar
• ••An unevitable thorough review dealingwith the value of anti-osteoporotic therapies.
   Google Scholar
• NAGANT DE DEUXCHAISNES C, DEVOGELAER JP: Restorative therapy of osteoporosis. In: iOsteoporosis: a guide to diagnosis and treatment. i Bröll H, Dambacher MA (Eda). Basel, Karger 18 (1996):207–264.
   Google Scholar
• NEER RM, ARNAUD CD, ZANCHETTA JR iet al: i Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. iN Engl.': Med. i (2001) 344:1434–1441.
   Google Scholar
• MEUNIER PJ, ROUX C, SEEMAN E iet al.: i The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. iN Engl. Med. i (2004) 350:459–468.
   Google Scholar
• BJARNASON NH, BJARNASON K, HAARBO J, ROSENQUIST C, CHRISTIANSEN C: Tibolone: prevention of bone loss in late postmenopausal women. i.1. Clin. Endocrinol Metab. i (1996) 81:2419–2422.
   Google Scholar
• KLOOSTERBOER HJ: Tibolone: asteroid with a tissue-specific mode of action. iSteroid Biochem. i (2001) 76:231–238.
   Web of Science ®Google Scholar
• DE GOOYER ME, DECKERS GH, SCHOONEN WGEJ, VERHEUL HAM, KLOOSTERBOER HJ: Receptor profiling and endocrine interactions of tibolone. iSteroids i (2003) 68:21–30.
   PubMed Web of Science ®Google Scholar
• ALBERTAZZI P, DI MICCO R, ZANARDI E: Tibolone: a review. iMaturitas i (1998) 30:295–305.
   PubMed Web of Science ®Google Scholar
• DAVIS SR: The effects of tibolone on mood and libido. iMenopause i (2002) 9:162–170.
   PubMed Web of Science ®Google Scholar
• CHLEBOWSKI RT, HENDRIX SL, LANGER RD iet al: i Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. iJAMA i (2003) 289:3243–3253.
   PubMed Web of Science ®Google Scholar
• •A frequently cited paper dealing with complications of HRT.
   Google Scholar
• LI CI, MALONE KE, PORTER PL iet al.: i Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. iJAMA i (2003) 289:3254–3263.
   Google Scholar
• BANKS E, BERAL V, BULL D, REEVES G and the MILLION WOMEN STUDY COLLABORATORS: Breast cancer and hormone-replacement therapy in the Million Women Study. iLancet i (2003) 362:419–427.
   PubMed Web of Science ®Google Scholar
• •A paper confirming the increased rate of breast cancer in postmenopausal women
   Google Scholar
• •• treated by HRT and suggesting that tibolone use could be complicated by a slightly increased incidence of breast cancer
   Google Scholar
• MUECK AO, LIPPERT C, SEEGER H, WALLWIENER D: Effects of tibolone on human breast cancer cells and human vascular coronary cells. iArch. Cynecol °Enter i (2003) 267:139–144.
   Google Scholar
• ZANDBERG P, PETERS JLM, DEMACKER M, DE REEDER EG, SMIT MJ, MEULEMAN DG: Comparison of the antiatherosclerotic effect of tibolone with that of estradiol and ethinyl estradiol in cholesterol-fed, ovariectomized rabbits. iMenopause i (2001) 8:96–105.
   PubMed Web of Science ®Google Scholar
• FARISH E, BARNES JF, ROLTON HA, SPOWART K, FLETCHER CD, HART DM: Effects of tibolone on lipoprotein(a) and HDL subfractions. iMaturitas i (1995) 20:215–219.
   Web of Science ®Google Scholar
• HAENGGI W, BERSINGER NA, MUELLER MD, BIRKHAEUSER MH: Decrease of serum endothelin levels with postmenopausal hormone replacement therapy or tibolone. iCynecol Endocrinol i (1999) 13:202–205.
   PubMed Web of Science ®Google Scholar
• EDERVEEN AGH, KLOOSTERBOER HJ: Tibolone exerts its protective effect on trabecular bone loss through the estrogen receptor. iJ. Bone Miner. Res. i (2001) 16:1651–1652.
   PubMed Web of Science ®Google Scholar
• LINDSAY R, HART DM, KRASZEWSKI A: Prospective double-blind trial of synthetic steroid (Org OD 14) for preventing postmenopausal osteoporosis. iBr. Med. J. i (1980) 280:1207–1209.
   PubMed Web of Science ®Google Scholar
• GEUSENS P, DEQUEKERJ, GIELEN J,SCHOT LPC: Non-linear increase in vertebral density induced by a synthetic steroid (Org OD14) in women with established osteoporosis. iMaturitas i (1991) 13:155–162.
   PubMed Web of Science ®Google Scholar
• BJARNASON NH, BJARNASON K, HASSAGER C, CHRISTIANSEN C: The response in spinal bone mass to tibolone treatment is related to bone turnover in elderly women. iBone i (1997) 20:151–155.
   Google Scholar
• BERNING B, KUIJK CV, KUIPER JW,COELINGH BENNINK HJT, KICOVIC PM, FAUSER BCJM: Effects of two doses of tibolone on trabecular and cortical bone loss in early postmenopausal women: a two-year randomized, placebo-controlled study. iBone i (1996) 19:395–399.
   Google Scholar
• STUDD J, ARNALA I, KICOVIC PM, ZAMBLERA D, KROGER H, HOLLAND N: A randomized study of tibolone on bone mineral density in osteoporotic postmenopausal women with previous fractures. i°Enter Cynecol. i (1998) 92:574–579.
   Google Scholar
• PAVLOV PW, GINSBURG J, KICOVIC PM, VAN DER SCHAAF DB, PRELEVIC G, COELINGH BENNINK HJT: Double-blind, placebo-controlled study of the effects of tibolone on bone mineral density in postmenopausal osteoporotic women with and without previous fractures. iCynecol Endocrinol i (1999) 13:230–237.
   PubMed Web of Science ®Google Scholar
• GALLAGHER JC, BAYLINK DJ, FREEMAN R, MCCLUNG M: Prevention of bone loss with tibolone in postmenopausal women: results of two randomized, double-blind, placebo-controlled, dose-finding studies. j. iClin. Endocrinol Metab. i (2001) 86:4717–4726.
   PubMed Web of Science ®Google Scholar
• ••The most detailed and the most completestudy on the action of tibolone on BMD .
   Google Scholar
• DEVOGELAER JP, DEPRESSEUX G, LE THI C, NAGANT DE DEUXCHAISNES C: Reproducibility of dual photon absorptiometry on novo type 22A in relation to various procedures and interfering factors. In: iBone mineral i measurement by photon absorptiomemy Dequeker J, Geusens P, Wahner HW (Eds), Leuven University Press, Leuven (1988):205–214.
   Google Scholar
• LYRITIS GP, KARPATHIOS S, BASDEKIS K iet al.: i Prevention of post-oophorectomy bone loss with tibolone. iMaturitas i (1995) 22:247–253.
   Google Scholar
• BEARDSWORTH SA, KEARNEY CE, PURDIE DW: Prevention of postmenopausal bone loss at lumbar spine and upper femur with tibolone: a two-year randomised controlled trial. iBr. J. Obstet. Cynaecol. i (1999) 106:678–683.
   PubMed Web of Science ®Google Scholar
• MILNER M, HARRISON RE GILLIGAN E, KELLY A: Bone density changes during two years treatment with tibolone or conjugated estrogens and norgestrel, compared with untreated controls in postmenopausal women. iMenopause i (2000) 7:327–333.
   PubMed Web of Science ®Google Scholar
• RYMERJ, ROBINSON J, FOGELMAN I: Ten years of treatment with tibolone 2.5 mg daily: effects on bone loss in postmenopausal women. iClimacteric i (2002) 5:390–398.
   Google Scholar
• PRELEVIC GM, BARTRAM C, WOOD J, OKOLO S, GINSBURG J: Comparative effects on bone mineral density of tibolone, transdermal estrogen and oral estrogen/progestogen therapy in postmenopausal women. iCynecol Endocrinol i (1996) 10:413–420.
   PubMed Web of Science ®Google Scholar
• LIPPUNER K, HAENGGI W, BIRKHAEUSER MH, CASEZ JP, JAEGER P: Prevention of postmenopausal bone loss using tibolone or conventional peroral or transdermal hormone replacement therapy with 1713-estradiol and dydrogesterone. iJ. Bone Miner. Res. i (1997) 12:806–812.
   PubMed Web of Science ®Google Scholar
• THIEBAUD D, BIGLER JM, RENTERIA S iet al.: i A 3-year study of prevention of postmenopausal bone loss: conjugated equine estrogens plus medroxyprogesterone acetate versus tibolone. iClimacteric i (1998) 1:202–210.
   Google Scholar
• CASTELO-BRANCO C, VICENTE JJ, FIGUERAS F iet al: i Comparative effects of estrogens plus androgens and tibolone on bone, lipid pattern and sexuality in postmenopausal women. iMaturitas i (2000) 34:161–168.
   PubMed Web of Science ®Google Scholar
• ROUX C, PELISSIER C, FECHTENBAUM J, LOISEAU-PERES S, BENHAMOU CL: Randomized, double-masked, 2-year comparision of tibolone with 17I3-estradiol and norethindrone acetate in preventing postmenopausal bone loss. iOsteoporos. Int. i (2002) 13:241–248.
   PubMed Web of Science ®Google Scholar
• DEVOGELAER JP, NAGANT DE DEUXCHAISNES C: Use of pamidronate in chronic and acute bone loss conditions. iMedicine i (1997) 57\(Suppl. 1):101–108.
   Google Scholar
• GREENSPAN SL, EMKEY RD, BONE HG 3rd iet al: i Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial. iAnn. Intern. Med. i (2002) 137:875–883.
   Google Scholar
• BERNING B, KUIJK CV, KUIPER JW,COELING H, BENNINK HJT, FAUSER BCJM: Increased loss of trabecular but not cortical bone density, 1 year after discontinuation of 2 year hormone replacement therapy with tibolone. iMaturitas i (1999) 31:151–159.
   PubMed Web of Science ®Google Scholar
• FELSON DT, ZHANG MPHY, HANNAN MT, KIEL DP, WILSON PWF, ANDERSON JJ: The effect of postmenopausal estrogen therapy on bonedensity in elderly women. iN Engl. I Med. i(1993) 329:1141–1146.
   PubMed Web of Science ®Google Scholar
• RYMER J, CHAPMAN MG, FOGELMAN I: Effect of tibolone on postmenopausal bone loss. iOsteoporos. i (1994) 4:314–319.
   PubMed Web of Science ®Google Scholar
• RYMER J, ROBINSON J, FOGELMAN I: Effects of 8 years of treatment wih tibolone 2.5 mg daily on postmenopausal bone loss. iOsteoporos Int. i (2001) 12:478–483.
   PubMed Web of Science ®Google Scholar
• HUBER J, PALACIOS S, BERGLUND L iet al.: i Effects of tibolone and continuous combined hormone replacement therapy on bleeding rates, quality of life and tolerability in postmenopausal women. iBr. °Enter Cynaecol. i (2002) 109:886–893.
   Google Scholar
• VALVIDIA I, ORTEGA D: Mammographic density in postmenopausal women treated with tibolone, estriol or conventional hormone replacement therapy. iClin. Drug Invest. i (2000) 20:101–107.
   Google Scholar
• CHRISTODOULAKOS GE, LAMBRINOUDAKI IV, VOURTSI AD, PANOULIS KP, KELEKIS DA, CREATSAS GC: Mammographic changes associated with raloxifene and tibolone therapy in postmenopausal women: a prospective study. iMenopause i (2002) 9:110–116.
   PubMed Web of Science ®Google Scholar
• REGINSTER J-Y, AGNUSDEI D, GENNARI C, KICOVIC PM: Association of tibolone and fluoride displays a pronounced effect on bone mineral density in postmenopausal osteoporotic women. iCynecol Endocrinol i (1999) 13:361–368.
   PubMed Web of Science ®Google Scholar
• BROOKE-WAVELL K, PRELEVIC GM, BARTRAM C, GINSBURG J: The influence of physical activity on the response of bone mineral density to 5 years tibolone. iMaturitas i (2000) 35:229–235.
   PubMed Web of Science ®Google Scholar
• DOREN M, NILSSON J-A, JOHNELL 0: Effects of specific postmenopausal hormone therapies on bone mineral density in post-menopausal women: a meta-analysis. iHuman Reprod. i (2003) 18:1737-1746.
   Google Scholar
• •A meta-analysis on postmenopausal hormone therapy of 2-year trials involving at least 60 women.
   Google Scholar
• COMPSTON JE, YAMAGUCHI K, CROUCHER PI, GARRAHAN NJ, LINDSAY PC, SHAW RW: The effects of gonadotropin-releasing hormone agonists on iliac crest cancellous bone structure in women with endometriosis. iBone i (1995) 16:261-267. Affiliation Professor Jean-Pierre Devogelaer MD Rheumatology Unit, UCL 5390, Saint-Luc University Hospital, Université catholique de Louvain, avenue Hippocrate 10, B-1200 Brussels, Belgium E-mail: [email protected]
   Google Scholar